title: Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect.
abstract: OBJECTIVE
  To develop and characterize new formulations of ziprasidone with a reduced food effect achieved by increasing exposure in the fasted state.
  
  
  METHODS
  Formulations were developed utilizing the following solubilization technologies: inclusion complex of ziprasidone mesylate and cyclodextrin, ziprasidone free base nano-suspension, and semi-ordered ziprasidone HCl in polymer matrix. Pharmacokinetic studies were conducted with these formulations to examine the bioavailability of test formulations in fasted and fed state compared to commercial capsules (Geodon®) dosed in the fed state.
  
  
  RESULTS
  All formulations containing solubilized ziprasidone showed either no food effect or a reduced food effect compared to commercial capsules. Two formulations when taken in the fasted or fed state were comparable to the commercial capsules dosed in the fed state with respect to total exposure. However, peak concentrations were ~30-40% higher.
  
  
  CONCLUSIONS
  Pharmacokinetic studies indicated solubilization technologies can be employed to successfully increase the extent of ziprasidone absorption in the fasted state, thereby reducing the food effect. Such formulations could provide simple and convenient dosing while retaining the familiar safety and efficacy profile of currently marketed capsules.
authors.affiliation: Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, USA. avinash.g.thombre@pfizer.com
authors.forename: Avinash G
authors.initials: AG
authors.lastname: Thombre
authors.forename: Scott M
authors.initials: SM
authors.lastname: Herbig
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Alderman
mesh_terms: D019540:Area Under Curve; D001682:Biological Availability; D018492:Dopamine Antagonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D005079:Excipients / Q000737:chemistry*; D005215:Fasting; D018565:Food-Drug Interactions; D006801:Humans; D010879:Piperazines / Q000493:pharmacokinetics* / Q000494:pharmacology; D012995:Solubility; D013844:Thiazoles / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D018492:Dopamine Antagonists; D005079:Excipients; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone